New cocktail aims to tackle tough pancreatic cancer

NCT ID NCT06941857

Recruiting now Disease control Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 2 trial tests a new drug called NC410 combined with standard chemotherapy (FOLFIRINOX) and immunotherapy drugs (nivolumab with or without ipilimumab) in 20 people with metastatic pancreatic cancer who have not had prior treatment. The main goal is to check safety and identify any unexpected side effects. Researchers will also track how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: NC410 (a biologic) plus FOLFIRINOX chemotherapy (oxaliplatin, irinotecan, folinic acid, fluorouracil) plus nivolumab with or without ipilimumab
What this could lead to: If successful, this could point toward a new combination treatment that improves outcomes for people with metastatic pancreatic cancer.
What could go wrong: This is a small, early-phase trial focused on safety, not yet proven to work. The combination may cause significant side effects and may not improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC PANCREATIC DUCTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

carcinoma malignant pancreatic neoplasm pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Show contact details

Study contacts

Contact

Email: •••••@•••••

Locations

Sidney Kimmel Comprehensive Cancer Center
RECRUITING

Baltimore, Maryland, 21231, United States

Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.